Viartis discussed the positive study results from Amarantus' Eltoprazine clinical trial published in BRAIN. Viartis highlighted that 5mg of Eltoprazine caused a significant reduction of L-dopa induced dyskinesias, as well as an antidyskinetic effect with 7.5 mg. Full study abstract and additional Parkinson's news available here: http://bit.ly/1yLLtG2